Advanced non-small cell lung cancer second-line treatment.docVIP

 PAGE \* MERGEFORMAT 5 Advanced non-small cell lung cancer second-line treatment [Abstract] Despite the advanced non-small cell lung cancer first-line chemotherapy have made some progress, but most patients with advanced non-small cell lung cancer after chemotherapy in the initial progress of the disease into the second-line treatment. Therefore, the current second-line treatment of non-small cell lung cancer has become the focus of clinical research. Second-line treatment drugs: docetaxel, pemetrexed, gefitinib, Erlotinib significantly prolonged survival of patients with improved quality of life. [Keywords:] non-small cell lung cancer; second-line; chemotherapy; targeted therapy Second-line therapy for advanced non-small-cell lung cancer XU Jian-ping. Peking Union Medical College, Chinese Academy of Medical Sciences Tumor Hospital. Beijing 100021, China [Abstract] Despite improvements in first-line chemotherapy, the majority of patients with advanced non-small-cell lung cancer (NSCLC) progress after initial therapy and are candidate for second-line therapy. As a result, second-line therapy has been a major focus of clinical cancer research. Second-line therapy with single-agent docetaxel, pemetrexed, gefitinib, or erlotinib offers patients a significant survival and QOL advantage. [Keywords:] NSCLC; second-line; chemotherapy; targeted therapy Lung cancer is the clinical one of the most common malignant tumors, including non-small cell lung cancer (non-small cell lung cancer, NSCLC) accounts for about 80%. And 60% of patients when treatment is already in the late treatment of major to adopt a comprehensive treatment of chemotherapy-based [1]. Currently used for clinical chemotherapy drugs such as Taxol (paclitaxel), Gemzar (gemcitabine), irinotecan (irinotecan), vinorelbine (vinorelbine) and other pairs of non-small cell lung cancer previously untreated patients with single-agent response rate was 20% ~ 30 %. When combined with cisplatin remission rate